Oropharynx
5
1
1
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
8 treatments under study, led by Purabond
Research Leaders
6 sponsors active, led by Yonsei University
Related Conditions
Often studied with 12 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 5 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (5)
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
PuraBond® and Pain Following Resection of Oral or Oropharyngeal Mucosal Lesions
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.
Do Traditional or Flavored Tongue Depressors Make for Easier Posterior Oropharynx Exams in Pediatric Patients
Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium
Research Network
Common Treatments
- Purabond1
- Grape Flavored Puritan Junior Tongue Depressor1
- Docetaxel1
- Durvalumab1
- Durvalumab Tremelimumab1
Active Sponsors
- Yonsei University1
- National Cancer Institute (NCI)1
- University of Liverpool1
- William Marsh Rice University1
- Brooke Army Medical Center1
Top Investigators
Icahn School of Medicine at Mount Sinai
National Cancer Institute (NCI)
Related Conditions
- Larynx2
- Hypopharynx2
- Human Papillomavirus Viruses1
- Hemostatics1
- Drug Therapy1